期刊文献+

达卡巴嗪原料药中N-亚硝基二甲胺和N-亚硝基二乙胺的UHPLC-APCI-MS/MS方法的建立 被引量:3

Establishment of method for determination of NDMA and NDEA in dacarbazine by UHPLC-APCI-MS/MS
下载PDF
导出
摘要 目的:采用UHPLC-APCI-MS/MS法测定达卡巴嗪原料药中的N-亚硝基二甲胺(NDMA)和N-亚硝基二乙胺(NDEA),建立控制该药品遗传毒性杂质的方法。方法:采用Kinetex F5色谱柱(3 mm×100 mm,2.6μm),流动相为0.1%甲酸溶液-甲醇,梯度洗脱,流速0.4 mL·min^(-1),柱温40℃,质谱离子化方式为APCI,正离子模式,多重反应监测,检测离子对为m/z 75.1/58.0(NDMA),103.0/47.0(NDEA)。结果:NDMA和NDEA在一定范围内线性关系良好(r>0.990),检出限溶液浓度分别为0.03030、0.003787 ng·mL(-1),精密度、稳定性试验满足检测要求,回收率为97~115%,RSD均小于5%。结论:本文建立的方法准确、快速灵敏、专属性强,可用于控制达卡巴嗪原料药中遗传毒性杂质NDMA和NDEA的含量。 Objective:To establish a method for determination of the genotoxic impurities of NDMA and NDEA in the active pharmaceutical ingredient of dacarbazine by UHPLC-APCI-MS/MS.Methods:The test was performed in Kinetex F5 column(3 mm×100 mm,2.6μm)under the gradient elution of 0.1%formic acid solution(mobile phase A)and methanol(mobile phase B).The flow rate was 0.4 mL·min-1,and the column temperature was 40℃.The ionization mode of mass spectrometry was APCI with positive ion mode,and determination was conducted in MRM scan mode by the external standard method.The ion pairs were m/z 75.1/58.0 for NDMA and m/z 103.0/47.0 for NDEA.Results:The established method for the separation and analysis of NDMA and NDEA was validated.The linear relationship in the linear range was good(r>0.990).The limits of detection were 0.03030 and 0.003787 ng·mL^(-1),respectively.The precision and stability results met the criteria,the recovery rate was 97%-115%,and all the relative standard deviations were less than 5%.Conclusion:The established method is accurate,rapid,sensitive and specific.It can be used for the quality control of the genotoxic impurities of NDMA and NDEA in API of Dacarbazine.
作者 陈卫 贾昌平 陈莉 初虹 王浩 柳根元 许明哲 CHEN Wei;JIA Changping;CHEN Li;CHU Hong;WANG Hao;LIU Genyuan;XU Mingzhe(Suzhou Institute for Drug Control,Suzhou 215104,China;Suzhou Terui Pharmaceutical Co.,Ltd.,Suzhou 215100,China;National Institutes for Food and Drug Control,Beijing 102629,China)
出处 《中国药品标准》 CAS 2021年第1期51-55,共5页 Drug Standards of China
关键词 达卡巴嗪 UHPLC-APCI-MS/MS N-亚硝基二甲胺 N-亚硝基二乙胺 Dacarbazine UHPLC-APCI-MS/MS NDMA NDEA
  • 相关文献

参考文献3

二级参考文献58

  • 1孙敬,詹文圆,陆瑞琪.肉制品中亚硝胺的形成机理及其影响因素分析[J].肉类研究,2008,22(1):18-23. 被引量:18
  • 2林昆,沈忠英,蔡树深,陆士新,郭黎平.我国南方食管癌高发区膳食亚硝胺水平及其相关因素研究[J].卫生研究,1997,26(4):266-269. 被引量:12
  • 3European Directorate for the Quality of Medicines and Healthcare Alkyl mesilate (methane sulfonate) impurities in mesilate salts [S]. Pharmeuropa, 2000, 12(1): 27.
  • 4Safety Working Party. Position paper on the limits of genotoxic impurities (CPMP/SWP/5199/02/ draft 2) IS]. London: Committee for Proprietary Medicinal Products, 2002.
  • 5ICH Expert Working Group. Impurities: Guideline for Residual Solvents Q3C, (R5) step 4 version [S]. European Union, Japan and USA: ICH HARMONISED TRIPARTITE (ICH), 2011: 6-7.
  • 6MUNRO I C, RENWICK A G, DANIELEWSKA-NIKIEI B. The threshold of toxicological concern (TTC) in risk assessment [J]. Toxicol Lett, 2008, 180(2): 151-156.
  • 7KROES R, RENWICK A G, CHEESEMANN M, et al. Structure-based thresholds of toxicological concern (TTC):Guidance for application to substances present at low levels in the diet [J]. Food Chem Toxiccol, 2004(42): 65-83.
  • 8MULLER L, MAUTHE R J, RILEY C M, et al. A rationale for specific impurities in pharmaceuticals that possess potential for gonotoxicity [J]. Regulat Toxieol Pharmacol, 2006(44): 198-211.
  • 9Committee for Medicinal Products for Human Use (CHMP) Guidelines on the limits of genotoxic impurities (CPMP/SWP/ 5199/02) [S]. London: European Medicines Agency Evaluation of Medicines for Human Use (EMEA), 2006.
  • 10CHMP Safety Working Party (SWP). Question & answer on the CHMP guideline on the limits of gonotoxic impurities [S]. EMEA/CHMP/QWP/251344/ 2006 Q&A, London: European Medicines Agency (EMA), 2010.

共引文献66

同被引文献67

引证文献3

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部